Cyclerion Therapeutics Stock Net Income
| CYCN Stock | USD 2.59 0.06 2.26% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Cyclerion Therapeutics' long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Net Loss | -3.1 M | -3.2 M | |
| Net Loss | -50.7 M | -53.2 M | |
| Net Loss | -3.1 M | -3.2 M | |
| Net Loss | (1.21) | (1.27) | |
| Net Income Per E B T | 1.50 | 0.90 |
Cyclerion | Net Income | Build AI portfolio with Cyclerion Stock |
Cyclerion Therapeutics Company Net Income Analysis
Cyclerion Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Cyclerion Therapeutics Net Income | (3.06 M) |
Most of Cyclerion Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyclerion Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cyclerion Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cyclerion Therapeutics is extremely important. It helps to project a fair market value of Cyclerion Stock properly, considering its historical fundamentals such as Net Income. Since Cyclerion Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cyclerion Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cyclerion Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cyclerion Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cyclerion Therapeutics reported net income of (3.06 Million). This is 100.9% lower than that of the Biotechnology sector and 104.36% lower than that of the Health Care industry. The net income for all United States stocks is 100.54% higher than that of the company.
Cyclerion Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclerion Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclerion Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclerion Therapeutics by comparing valuation metrics of similar companies.Cyclerion Therapeutics is currently under evaluation in net income category among its peers.
Cyclerion Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cyclerion Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cyclerion Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Cyclerion Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Cyclerion Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cyclerion Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cyclerion Therapeutics' value.| Shares | Advisor Group Holdings, Inc. | 2025-03-31 | 130 | Mccormack Advisors International | 2025-03-31 | 100.0 | Activest Wealth Management | 2025-03-31 | 100.0 | Bank Of America Corp | 2025-03-31 | 19.0 | Sbi Securities Co Ltd | 2025-03-31 | 11.0 | Bnp Paribas Arbitrage, Sa | 2025-03-31 | 5.0 | Northwestern Mutual Wealth Management Co | 2025-03-31 | 1.0 | Mfn Partners Management, Lp | 2024-12-31 | 0.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Tyndall Management, Llc | 2025-03-31 | 164.8 K | Tyndall Capital Partners L P | 2025-03-31 | 164.8 K |
Cyclerion Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (1.41) % | ||||
| Operating Margin | (17.99) % | ||||
| Current Valuation | 5.6 M | ||||
| Shares Outstanding | 3.56 M | ||||
| Shares Owned By Insiders | 32.72 % | ||||
| Shares Owned By Institutions | 12.21 % | ||||
| Number Of Shares Shorted | 17.18 K | ||||
| Price To Earning | (0.59) X | ||||
| Price To Book | 1.05 X | ||||
| Price To Sales | 4.44 X | ||||
| Revenue | 2 M | ||||
| Gross Profit | 2.08 M | ||||
| EBITDA | (3.63 M) | ||||
| Net Income | (3.06 M) | ||||
| Cash And Equivalents | 30.32 M | ||||
| Cash Per Share | 0.70 X | ||||
| Total Debt | 725 K | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | 2.87 X | ||||
| Cash Flow From Operations | (4.33 M) | ||||
| Short Ratio | 0.51 X | ||||
| Earnings Per Share | (1.15) X | ||||
| Target Price | 4.0 | ||||
| Beta | 1.55 | ||||
| Market Capitalization | 9.24 M | ||||
| Total Asset | 9.57 M | ||||
| Retained Earnings | (267.49 M) | ||||
| Working Capital | 3.5 M | ||||
| Current Asset | 109.19 M | ||||
| Current Liabilities | 18.4 M | ||||
| Net Asset | 9.57 M |
About Cyclerion Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclerion Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclerion Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclerion Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cyclerion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclerion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclerion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Cyclerion Stock
The ability to find closely correlated positions to Cyclerion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclerion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclerion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclerion Therapeutics to buy it.
The correlation of Cyclerion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclerion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclerion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclerion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Cyclerion Therapeutics Piotroski F Score and Cyclerion Therapeutics Altman Z Score analysis. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.15) | Revenue Per Share | Quarterly Revenue Growth 0.141 | Return On Assets | Return On Equity |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.